Tributary Capital Management’s Idexx Laboratories IDXX Stock Holding History

Tributary Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,600	Closed	-$3.06M	–	183
2022 Q1	$3.06M	Buy	5,600 +800	+17%	+$421K	0.24%	68
2021 Q4	$3.16M	Sell	4,800 -800	-14%	-$502K	0.24%	70
2021 Q3	$3.48M	Hold	5,600	–	–	0.27%	69
2021 Q2	$3.54M	Hold	5,600	–	–	0.27%	65
2021 Q1	$2.74M	Hold	5,600	–	–	0.21%	76
2020 Q4	$2.8M	Hold	5,600	–	–	0.2%	76
2020 Q3	$2.2M	Buy	+5,600	New	+$2.07M	0.19%	89

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Tributary Capital Management's IDXX Position: Q2 2022 in Review

Tributary Capital Management sold out of Idexx Laboratories (IDXX) in Q2 2022, closing a stake of 5,600 shares — an estimated $3.06M sold.

Tributary Capital Management first reported a position in IDXX in Q3 2020 and held it in 7 quarters. The position peaked at $3.54M in Q2 2021. 956 funds tracked by Wall St. Rank hold IDXX as of Q2 2022.

Tributary Capital Management reported no remaining Idexx Laboratories position as of Q2 2022 after selling out during the quarter.
Tributary Capital Management sold 5,600 Idexx Laboratories shares in Q2 2022, an estimated $3.06M.
Tributary Capital Management first reported a position in Idexx Laboratories in Q3 2020 and held it in 7 quarters.
Tributary Capital Management's Idexx Laboratories position peaked at $3.54M in Q2 2021.
956 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2022.

Based on Tributary Capital Management's 13F filing for Q2 2022, filed 19 Jul 2022.